Genfit S.A. (NASDAQ:GNFT – Get Free Report) shares fell 6.1% during trading on Monday . The stock traded as low as $3.57 and last traded at $3.57. 5,229 shares were traded during mid-day trading, a decline of 89% from the average session volume of 47,872 shares. The stock had previously closed at $3.80.
Wall Street Analyst Weigh In
Separately, HC Wainwright raised their target price on Genfit from $9.00 to $11.00 in a research note on Monday, July 3rd.
Genfit Stock Down 6.1 %
Hedge Funds Weigh In On Genfit
Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SNC raised its holdings in Genfit by 1,992.8% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 11,845 shares of the company’s stock worth $43,000 after acquiring an additional 11,279 shares during the last quarter. Envestnet Asset Management Inc. purchased a new position in Genfit in the 3rd quarter worth approximately $70,000. Optiver Holding B.V. raised its holdings in Genfit by 33.5% in the 4th quarter. Optiver Holding B.V. now owns 23,678 shares of the company’s stock worth $103,000 after acquiring an additional 5,945 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in Genfit by 29.6% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 24,462 shares of the company’s stock worth $99,000 after acquiring an additional 5,580 shares during the last quarter. Finally, Citadel Advisors LLC raised its holdings in Genfit by 181.8% in the 3rd quarter. Citadel Advisors LLC now owns 35,319 shares of the company’s stock worth $129,000 after acquiring an additional 22,786 shares during the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.
Genfit Company Profile
Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.
- Five stocks we like better than Genfit
- The How and Why of Investing in Large-Cap Stocks
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What is the FTSE 100 index?
- 5 Reasons Mullen Automotive is About to Turn a Corner
- What is a Low P/E Ratio and What Does it Tell Investors?
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.